Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 11, 2015 04:14 ET | Source: Elsalys Biotech

Elsalys Biotech :THE TYROMAB CONSORTIUM, HEADED BY ELSALYS BIOTECH, OBTAINS 1.57 MILLION EUROS FROM THE SINGLE INTERMINISTERIAL FUND (FUI)

THE TYROMAB CONSORTIUM, HEADED BY ELSALYS BIOTECH, OBTAINS 1.57 MILLION EUROS FROM THE SINGLE INTERMINISTERIAL FUND (FUI) Supported by ElsaLys Biotech, PX'Therapeutics, a subsidiary...
September 11, 2015 04:08 ET | Source: Elsalys Biotech

Elsalys Biotech :THE TYROMAB CONSORTIUM, HEADED BY ELSALYS BIOTECH, OBTAINS 1.57 MILLION EUROS FROM THE SINGLE INTERMINISTERIAL FUND (FUI)

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} THE TYROMAB CONSORTIUM, HEADED BY ...
September 11, 2015 04:08 ET | Source: Elsalys Biotech

Elsalys Biotech : LE CONSORTIUM TYROMAB, DONT ELSALYS BIOTECH EST LE CHEF DE FILE, OBTIENT 1,57 MILLION D'EUROS DU FONDS UNIQUE INTERMINISTÉRIEL

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} LE CONSORTIUM TYROMAB, DONT ELSALYS...
July 02, 2015 05:17 ET | Source: Elsalys Biotech

Elsalys Biotech acquires a first-in-class antibody with a dual biological mechanism of action: anti-angiogenic and immuno-modulator

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Elsalys Biotech acquires a...

keyboard_arrow_left Previous Page